Prime Medicine
PRME
3.90
+0.40
+11.43%
Prime Medicine
US · PRME
#3501 by market cap
Listed 2022
3.90
+0.40
+11.43%
Live - 5344 symbols - heartbeat 525s ago
· 2026-10-08 09:09
Pre-market
3.85
-1.30%
After-hours
3.88
-0.42%
Overnight
3.94
+1.03%
- Market cap
- 707.37M
- P/E (TTM)i
- -3.71
- P/Bi
- 17.81
- EPSi
- -1.35
- Div yieldi
- 0.00%
- 52W posi
- 31%
Reader sentiment
Are you bullish or bearish on PRME?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.20, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 6 years
Latest year +55.28% YoY
Margins
- Operating margin
- -4,498.06%
- Net margin
- -4,342.44%
Key ratios & quality
- Altman Z-Scorei
- -3.20
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 5.21M | 0 | 0 | 0 | 2.98M | 4.63M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 3.16M | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Research & development | 2.98M | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Operating profit | -932.00K | -84.47M | -116.54M | -191.29M | -202.47M | -208.35M |
| Pretax profit | -1.54M | -165.85M | -122.77M | -198.41M | -195.88M | -201.14M |
| Tax | 1.87M | -486.00K | -948.00K | -279.00K | -- | -- |
| Net profit | -3.41M | -165.37M | -121.82M | -198.13M | -195.88M | -201.14M |
| Basic EPS | 0 | -3 | -4 | -2 | -2 | -1 |
| Diluted EPS | -0.07 | -2.56 | -4.19 | -2.18 | -1.65 | -1.35 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.45M | 1.12M | 1.23M | 838.00K | 856.00K | 1.15M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.28M | 13.12M | 11.21M | 14.74M | 17.41M | 11.04M |
| Research & development | 40.56M | 41.38M | 43.99M | 34.71M | 34.11M | 33.40M |
| Operating profit | -52.39M | -53.38M | -53.97M | -48.61M | -50.65M | -43.29M |
| Pretax profit | -51.89M | -52.59M | -50.58M | -46.08M | -49.12M | -42.11M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -51.89M | -52.59M | -50.58M | -46.08M | -49.12M | -42.11M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.40 | -0.41 | -0.32 | -0.24 | -0.28 | -0.24 |
Balance sheet
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total current assets | 53.40M | 270.58M | 296.62M | 142.98M | 211.89M | 181.29M |
| Cash & ST investments | 53.33M | 269.62M | 293.92M | 121.67M | 190.44M | 177.68M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 54.78M | 301.86M | 360.31M | 193.85M | 297.51M | 342.73M |
| Total current liabilities | 19.44M | 57.98M | 26.71M | 56.42M | 37.96M | 37.45M |
| Short-term debt | -- | 7.34M | 11.69M | 9.28M | 3.61M | 8.14M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 21,309,000.00 | 62,296,000.00 | 44,044,000.00 | 60,780,000.00 | 144,359,000.00 | 221,865,000.00 |
| Total equity | 33.47M | 239.56M | 316.27M | 133.07M | 153.15M | 120.87M |
| Retained earnings | -6.01M | -171.38M | -293.20M | -491.33M | -687.21M | -888.35M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 163.77M | 121.29M | 231.41M | 181.29M | 137.89M | 96.80M |
| Cash & ST investments | 144.26M | 101.75M | 213.29M | 177.68M | 135.50M | 47.45M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 328.16M | 279.01M | 385.01M | 342.73M | 294.73M | 249.04M |
| Total current liabilities | 34.29M | 34.11M | 35.02M | 37.45M | 36.29M | 31.69M |
| Short-term debt | 6.86M | 7.26M | 7.71M | 8.14M | 8.55M | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 221,239,000.00 | 218,149,000.00 | 223,191,000.00 | 221,865,000.00 | 218,030,000.00 | 209,231,000.00 |
| Total equity | 106.92M | 60.86M | 161.82M | 120.87M | 76.70M | 39.81M |
| Retained earnings | -739.10M | -791.69M | -842.28M | -888.35M | -937.48M | 979.59M |
Cash flow
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -5.54M | -34.08M | -131.83M | -165.41M | -122.87M | -162.56M |
| Depreciation & amortization | 43.00K | 568.00K | 2.22M | 4.65M | 6.13M | 7.32M |
| Free cash flow | -6.18M | -38.23M | -147.92M | -174.14M | -130.16M | -167.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 185.32M | 0 | 170.14M | 138.39M |
| Ending cash balance | 36.98M | 198.55M | 201.12M | 55.07M | 196.54M | 76.72M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -48.86M | -41.41M | -35.04M | -37.26M | -42.71M | -41.05M |
| Depreciation & amortization | 1.70M | 1.86M | 1.88M | 1.88M | 1.86M | 1.79M |
| Free cash flow | -51.28M | -42.98M | -35.29M | -37.55M | -42.92M | -41.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | 10.00K | -- | -- |
| Ending cash balance | 105.94M | 67.50M | 85.09M | 76.72M | 77.80M | 61.14M |
Returns & efficiency
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| ROE %i | -216.21 | -- | -177.48 | -88.19 | -136.88 | -146.81 |
| ROA %i | -9.23 | -103.25 | -42.89 | -71.51 | -79.73 | -62.83 |
| ROIC %i | -216.21 | -- | -142.60 | -80.59 | -117.07 | -95.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -17.89 | -- | -- | -- | -6,787.36 | -4,498.06 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.75 | 4.67 | 11.10 | 2.53 | 5.58 | 4.84 |
| Quick ratioi | 2.74 | 4.65 | 11.00 | 2.16 | 5.02 | 4.74 |
| Debt / assetsi | 0.00 | 3.45 | 7.98 | 7.03 | 13.71 | 33.97 |
| LT debt / equityi | -- | -- | 5.39 | 3.27 | 24.28 | 89.59 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -115.21 | -154.81 | -112.34 | -146.81 | -216.07 | -18.24 |
| ROA %i | -63.17 | -73.98 | -54.98 | -62.83 | -63.69 | -71.16 |
| ROIC %i | -79.92 | -97.16 | -79.08 | -95.21 | -96.53 | -16.87 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -5,369.68 | -4,116.57 | -3,412.48 | -4,498.06 | -5,121.77 | -4,824.94 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 4.78 | 3.56 | 6.61 | 4.84 | 3.80 | 3.05 |
| Quick ratioi | 4.21 | 2.99 | 6.09 | 4.74 | 3.73 | 1.50 |
| Debt / assetsi | 36.92 | 42.91 | 30.68 | 33.97 | 38.85 | 45.16 |
| LT debt / equityi | 106.89 | 184.81 | 68.24 | 89.59 | 138.16 | 5.18 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 09:09:33 · For reference only, not investment advice and not tailored to your situation.